IMRX
Immuneering·NASDAQ
--
--(--)
--
--(--)
6.17 / 10
Outperform
Analyst consensus is overwhelmingly bullish (Strong Buy 50% and Buy 50% from two providers), and fund-flow analysis indicates positive liquidity with an overall score of 7.7/10. Block and extra-large flows are positive, while small, medium, and large flows lean negative, suggesting institutional accumulation outweighs retail selling. Sentiment score of 6.17 supports this positive flow narrative.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-31
InstitutionLeerink Partners
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of IMRX?
- IMRX holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.17/10 (Outperform).
